Quantinno Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.92M Buy
15,826
+3,401
+27% +$740K ﹤0.01% 1871
2026
Q2
$3.04M Buy
12,425
+928
+8% +$201K ﹤0.01% 1624
2026
Q1
$1.94M Buy
11,497
+5,019
+77% +$867K ﹤0.01% 1639
2025
Q4
$1.18M Buy
6,478
+3,636
+128% +$508K ﹤0.01% 1672
2025
Q3
$345K Buy
2,842
+668
+31% +$75.2K ﹤0.01% 2339
2025
Q2
$227K Buy
+2,174
New +$230K ﹤0.01% 2246

Other funds holding AXSM

Quantinno Capital Management's AXSM Position: Q3 2026 in Review

Quantinno Capital Management increased its Axsome Therapeutics (AXSM) stake by 27% in Q3 2026, buying an estimated $740K and bringing the position to 15,826 shares worth $2.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Quantinno Capital Management first reported a position in AXSM in Q2 2025 and has held it in 6 quarters since. The position peaked at $3.04M in Q2 2026. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Quantinno Capital Management held 15,826 shares of Axsome Therapeutics worth $2.92M as of Q3 2026.
  • Quantinno Capital Management bought 3,401 Axsome Therapeutics shares in Q3 2026, an estimated $740K.
  • Axsome Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q3 2026, its #1871 holding.
  • Quantinno Capital Management first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Quantinno Capital Management's Axsome Therapeutics position peaked at $3.04M in Q2 2026.
  • 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Quantinno Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.